|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:adjuvant
|
aluminum hydroxide
|
|
gptkbp:alsoKnownAs
|
gptkb:CoronaVac
|
|
gptkbp:antigen
|
whole inactivated virus
|
|
gptkbp:approvedBy
|
2020
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:countryOfOrigin
|
gptkb:China
|
|
gptkbp:developedBy
|
gptkb:Sinovac_Biotech
|
|
gptkbp:distribution
|
global
|
|
gptkbp:dosesRequired
|
2
|
|
gptkbp:effect
|
varies by country and study
|
|
gptkbp:emergencyServices
|
gptkb:Brazil
gptkb:Chile
gptkb:Egypt
gptkb:Hungary
gptkb:Indonesia
gptkb:Malaysia
gptkb:Mexico
gptkb:Philippines
gptkb:Thailand
gptkb:Turkey
gptkb:World_Health_Organization
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sinovac COVID-19 vaccine
|
|
gptkbp:includedInCOVAX
|
yes
|
|
gptkbp:intervalBetweenDoses
|
2–4 weeks
|
|
gptkbp:manufacturer
|
gptkb:Brazil
gptkb:China
gptkb:Egypt
gptkb:Indonesia
gptkb:Malaysia
gptkb:Turkey
|
|
gptkbp:regulates
|
approved for emergency use in multiple countries
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
nausea
diarrhea
fatigue
headache
muscle pain
allergic reaction
pain at injection site
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:suitableFor
|
adults 18 years and older
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:technology
|
inactivated SARS-CoV-2 virus
|
|
gptkbp:type
|
inactivated virus vaccine
|
|
gptkbp:usedIn
|
over 50 countries
|
|
gptkbp:WHOEmergencyUseListing
|
2021-06-01
|
|
gptkbp:bfsParent
|
gptkb:COVID-19
gptkb:COVID-19_pandemic
|
|
gptkbp:bfsLayer
|
4
|